Literature DB >> 10923772

Prevalence and severity of symptoms in terminal cancer patients: a study in Taiwan.

T Y Chiu1, W Y Hu, C Y Chen.   

Abstract

This paper reports a prospective study conducted between September 1997 and July 1998 in 232 consecutive patients with terminal cancer. A structured data collection form was used daily to evaluate symptoms, which were analyzed at the time of admission, 1 week after admission and 48 h before death. Terminal cancer patients in this study were polysymptomatic. There were no statistically significant differences in the prevalence of most symptoms with the primary site of cancer. The majority of symptoms improved at the end of the 1st week after admission, but many symptoms worsened just before death. The high prevalence of symptoms and lack of significant difference among primary tumor sites may be related to shorter survival times caused by late referral, which is common in Taiwan.

Entities:  

Mesh:

Year:  2000        PMID: 10923772     DOI: 10.1007/s005209900112

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  20 in total

1.  Non-scheduled consultation in oncologic patients. How many of them are true emergencies? An observational prospective study.

Authors:  F A Díaz-Couselo; J M O'Connor; A Nervo; G Tossen; A Guercovich; C Puparelli; C Coronado; V Costanzo; M Zylberman
Journal:  Support Care Cancer       Date:  2004-01-20       Impact factor: 3.603

2.  Surrogate decision-making in Korean patients with advanced cancer: a longitudinal study.

Authors:  June Koo Lee; Bhumsuk Keam; Ah Reum An; Tae Min Kim; Se-Hoon Lee; Dong-Wan Kim; Dae Seog Heo
Journal:  Support Care Cancer       Date:  2012-05-31       Impact factor: 3.603

3.  Symptom experience in the last year of life among individuals with cancer.

Authors:  Ardith Z Doorenbos; Charles W Given; Barbara Given; Natalya Verbitsky
Journal:  J Pain Symptom Manage       Date:  2006-11       Impact factor: 3.612

4.  Certain bio-psychosocial-spiritual problems associated with dyspnea among advanced cancer patients in Taiwan.

Authors:  Chih-Te Ho; Hua-Shui Hsu; Chia-Ing Li; Chiu-Shong Liu; Chin-Yu Lin; Cheng-Chieh Lin; Wen-Yuan Lin
Journal:  Support Care Cancer       Date:  2011-09-27       Impact factor: 3.603

5.  Comparison of timing and decision-makers of do-not-resuscitate orders between thoracic cancer and non-cancer respiratory disease patients dying in a Japanese acute care hospital.

Authors:  Kosuke Fujimoto; Seigo Minami; Suguru Yamamoto; Yoshitaka Ogata; Taro Koba; Shinji Futami; Yuh Nishijima; Moto Yaga; Kentaro Masuhiro; Kiyoshi Komuta
Journal:  Support Care Cancer       Date:  2014-01-12       Impact factor: 3.603

Review 6.  A cross-cultural comparison of hospice development in Japan, South Korea, and Taiwan.

Authors:  Anne P Glass; Li-Kuang Chen; Eunju Hwang; Yuzuho Ono; Lusine Nahapetyan
Journal:  J Cross Cult Gerontol       Date:  2010-03

7.  Descriptive analysis of clinical factors affecting terminally ill cancer patients.

Authors:  A M Jiménez-Gordo; J Feliu; B Martínez; J de-Castro; N Rodríguez-Salas; N Sastre; Y Vilches; E Espinosa; J R Rodríguez-Aizcorbe; M González-Barón
Journal:  Support Care Cancer       Date:  2008-06-05       Impact factor: 3.603

8.  Determinants of complicated grief in caregivers who cared for terminal cancer patients.

Authors:  Yu-Wen Chiu; Chia-Tsuan Huang; Shao-Min Yin; Yung-Cheng Huang; Ching-Hsin Chien; Hung-Yi Chuang
Journal:  Support Care Cancer       Date:  2009-10-09       Impact factor: 3.603

9.  A computer-assisted model for predicting probability of dying within 7 days of hospice admission in patients with terminal cancer.

Authors:  Jui-Kun Chiang; Yu-Hsiang Cheng; Malcolm Koo; Yee-Hsin Kao; Ching-Yu Chen
Journal:  Jpn J Clin Oncol       Date:  2010-01-22       Impact factor: 3.019

10.  A proposed prognostic 7-day survival formula for patients with terminal cancer.

Authors:  Jui-Kun Chiang; Ning-Sheng Lai; Mei-Huang Wang; Shi-Chi Chen; Yee-Hsin Kao
Journal:  BMC Public Health       Date:  2009-09-29       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.